This inventor holds 1 USPTO granted patent. Top assignees: Chinese Academy of Medical Sciences, Hebei Medfaith Pharmaceutical Technology Co., Ltd.. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 129 
1 out of 1 Years Active: 2021
Title: Innovations of Hongwei He in Liver Fibrosis Treatment
Introduction
Hongwei He is a notable inventor based in Beijing, China. He has made significant contributions to the field of medicine, particularly in the treatment of liver fibrosis. His innovative work focuses on the use of specific compounds to inhibit liver damage and improve liver function.
Latest Patents
Hongwei He holds a patent for the use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis. This invention is crucial in the medical field as it addresses liver injuries and diseases associated with liver fibrosis. The patent outlines methods for modulating collagen content in liver tissue and inhibiting the activity of genes related to liver fibrosis.
Career Highlights
Throughout his career, Hongwei He has worked with prominent organizations such as Hebei Medfaith Pharmaceutical Technology Co., Ltd. and the Chinese Academy of Medical Sciences. His experience in these institutions has allowed him to advance his research and contribute to significant medical innovations.
Collaborations
Hongwei He has collaborated with notable colleagues, including Hongwei Tian and Xingang Wang. These partnerships have facilitated the exchange of ideas and expertise, further enhancing his research efforts.
Conclusion
Hongwei He is a distinguished inventor whose work in liver fibrosis treatment showcases the potential of innovative medical solutions. His contributions are vital for advancing healthcare and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile